CBD and SSRIs: CYP2D6, CYP2C19, and the pharmacogenomic variable
Bottom line. SSRIs are metabolized primarily by CYP2D6 and CYP2C19 — both inhibited by CBD. Anderson 2022 documented a clinically significant CBD-fluoxetine interaction in a CYP2D6 poor metabolizer. The interaction risk varies substantially by which SSRI you take and your individual CYP genotype. Talk to your prescriber before combining; pharmacogenomic testing (if available) is a useful input for this conversation.
Key takeaways
- Most SSRIs rely on CYP2D6 and/or CYP2C19 for metabolism; CBD inhibits both.
- Anderson 2022 documented a CBD-fluoxetine interaction that was clinically significant in a CYP2D6 poor metabolizer.
- CYP2D6 genotype (poor vs normal vs ultrarapid metabolizer) substantially changes your baseline risk.
- Signs of SSRI over-exposure include nausea, agitation, tremor, and insomnia — similar to SSRI side effects at higher doses.
- Do not adjust SSRIs independently. Tell your prescriber before combining CBD with any antidepressant.
What the science says
Anderson 2022 — the pharmacogenomic case
Anderson 2022 documented a CBD-fluoxetine interaction in a patient who was a CYP2D6 poor metabolizer — meaning their enzyme was already clearing fluoxetine slowly. Adding CBD, which further inhibits CYP2D6, raised fluoxetine plasma levels to a range associated with adverse effects. The case illustrates why the same CBD dose can have very different effects on SSRI levels depending on your genetics.
The broader evidence base
Bansal 2023's n=18 RCT confirmed CBD raises CYP2C19 and CYP2D6 substrate plasma exposure significantly at research doses. Stöllberger 2023 identified most SSRIs as CYP2D6 and/or CYP2C19 substrates — meaning they share metabolic pathways CBD affects. Nachnani 2024's systematic review includes SSRI interactions in its catalog.
Per-SSRI CYP profile
| SSRI | Brand | Primary CYP | CBD interaction concern |
|---|---|---|---|
| Fluoxetine | Prozac | CYP2D6, CYP2C9 | Documented (Anderson 2022) |
| Sertraline | Zoloft | CYP2D6, CYP2C19 | Plausible — dual pathway overlap |
| Escitalopram | Lexapro | CYP2C19 (primary) | Plausible — CYP2C19 inhibited by CBD |
| Citalopram | Celexa | CYP2C19 (primary) | Plausible — same as escitalopram |
| Paroxetine | Paxil | CYP2D6 (primary) | Higher concern — strong CYP2D6 substrate |
What this means for you
- Tell your prescriber before starting CBD. Mention which SSRI, at what dose, and for how long. If you've had pharmacogenomic testing, share the CYP2D6 result — it's directly relevant to your risk.
- Know the signs of SSRI over-exposure. Nausea, agitation, tremor, insomnia, and sexual dysfunction at levels beyond your usual experience are signs that SSRI plasma levels may be elevated. These overlap with serotonin syndrome precursors — if severe, contact your prescriber.
- Serotonin syndrome risk is indirect. CBD doesn't directly affect serotonin, but raising SSRI plasma levels through CYP inhibition could push someone closer to serotonin excess. This is a pharmacokinetic concern, not a direct pharmacodynamic one. The risk is real but the mechanism is indirect.
- Start low if your prescriber approves. 10–15mg CBD/day with slow titration (see the titration protocol) minimizes the CYP inhibition magnitude while you establish a baseline.
- Consider format. The topical roll-on has minimal systemic absorption and negligible CYP impact — useful for localized joint or muscle use if you want to avoid systemic CBD while on an SSRI.
Frequently asked questions
Can I take CBD if I'm on an SSRI?
Talk to your prescriber first. SSRIs use CYP2D6 and CYP2C19, both inhibited by CBD. The risk varies by which SSRI and your CYP genotype. Your prescriber can discuss monitoring.
Can CBD help with depression or anxiety alongside my SSRI?
CBD has anxiolytic signal in published research, but we cannot recommend it as a treatment for depression or anxiety — that's medical territory. Adding CBD without prescriber knowledge risks raising SSRI plasma levels unexpectedly. Raise this with your psychiatrist or prescriber.
What is CYP2D6 genotype and why does it matter?
CYP2D6 determines how fast you clear drugs that use that enzyme. Poor metabolizers (already slow) are most at risk when CBD further inhibits the enzyme. Anderson 2022 documented this specifically for fluoxetine. If you've had pharmacogenomic testing, share the result with your prescriber.
References
- Anderson LL et al. (2022). Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. PMID 35790281
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Nachnani R et al. (2024). Cannabidiol-prescription drug interactions: a systematic review. PMID 38868665
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924